-0.35%
3.05%
0.76%
-5.02%
-27.35%
-64.32%
-20.58%
AI Spotlight on INMD
Company Description
InMode Ltd.designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally.The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.The company was formerly known as Invasix Ltd.and changed its name to InMode Ltd.
in November 2017.InMode Ltd.was incorporated in 2008 and is headquartered in Yokneam, Israel.
Market Data
| Last Price | 17.21 |
| Change Percentage | -0.35% |
| Open | 17.27 |
| Previous Close | 17.27 |
| Market Cap ( Millions) | 1456 |
| Volume | 898045 |
| Year High | 26.8 |
| Year Low | 14.87 |
| M A 50 | 17.69 |
| M A 200 | 17.49 |
Financial Ratios
| FCF Yield | 11.02% |
| Dividend Yield | 0.00% |
| ROE | 19.89% |
| Debt / Equity | 0.72% |
| Net Debt / EBIDTA | -116.85% |
| Price To Book | 1.8 |
| Price Earnings Ratio | 8.63 |
| Price To FCF | 9.07 |
| Price To sales | 3.44 |
| EV / EBITDA | 9.5 |
News
- Jan -28 - InMode: A Clear Bargain With Unique Risks
- Jan -16 - InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced
- Jan -15 - DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback
- Jan -10 - InMode: Clearly, I Was Too Optimistic (Rating Downgrade)
- Jan -08 - InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M
- Dec -12 - InMode: Product Origination And Undervaluation Make The Stock A Buy
- Nov -06 - InMode to Present at Upcoming Investor Conferences
- Nov -05 - InMode: $25/Share Is Closer Than You Think
- Oct -31 - InMode: A Deep Dive After Q3 Earnings
- Oct -30 - InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript
- Oct -30 - InMode (INMD) Q3 Earnings and Revenues Beat Estimates
- Oct -30 - InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)
- Oct -28 - Pomerantz Law Firm Announces Filing Deadline in Class Action Against InMode Ltd. and Certain Officers – INMD
- Oct -24 - InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories
- Oct -10 - InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024
- Oct -04 - Stock Picks From Seeking Alpha's September 2024 New Analysts
- Oct -01 - InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy
- Sep -19 - InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)
- Sep -10 - InMode Announces Share Repurchase Program of Up to 7.68 Million Shares
- Sep -06 - InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Aesthetic Solutions
Expected Growth : 15 %
What the company do ?
Aesthetic Solutions from InMode Ltd. offer minimally invasive, non-surgical treatments for skin rejuvenation, hair removal, and body contouring using advanced technologies like radiofrequency and light-based systems.
Why we expect these perspectives ?
InMode's Aesthetic Solutions segment growth is driven by increasing demand for minimally invasive treatments, rising adoption of RF-based technologies, and expanding global distribution channels. Additionally, the company's focus on innovation, strategic partnerships, and strong marketing efforts contribute to its 15% growth rate.
Inmode Ltd. Products
| Product Range | What is it ? |
|---|---|
| Minimally Invasive Products | InMode's minimally invasive products are designed for various medical specialties, including dermatology, plastic surgery, and ophthalmology. These products enable precise and controlled energy delivery, minimizing tissue damage and promoting faster recovery. |
| Radiofrequency (RF) Products | InMode's RF products utilize proprietary technology to deliver controlled heat energy, stimulating collagen production and tissue contraction. This results in improved skin texture, reduced wrinkles, and enhanced skin elasticity. |
| Laser Products | InMode's laser products are designed for various medical and aesthetic applications, including hair removal, skin rejuvenation, and vascular lesion treatment. |
| Microneedling Products | InMode's microneedling products utilize minimally invasive, percutaneous collagen induction therapy to stimulate collagen production, improving skin texture and reducing fine lines and wrinkles. |
| Body Contouring Products | InMode's body contouring products are designed for non-invasive fat reduction, skin tightening, and cellulite treatment. |
InMode Ltd.'s Porter Forces
Threat Of Substitutes
InMode Ltd. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the medical aesthetics industry.
Bargaining Power Of Customers
InMode Ltd.'s customers are primarily medical professionals and clinics, who have limited bargaining power due to the specialized nature of the company's products and services.
Bargaining Power Of Suppliers
InMode Ltd. has a diversified supplier base, which reduces the bargaining power of individual suppliers, and the company's strong financial position also gives it negotiating power.
Threat Of New Entrants
The medical aesthetics industry is attractive and growing, with low barriers to entry, making it an attractive market for new entrants, which poses a significant threat to InMode Ltd.'s market share.
Intensity Of Rivalry
InMode Ltd. operates in a competitive market with several established players, but the company's innovative products and strong marketing efforts help it to maintain a competitive edge.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.13% |
| Debt Cost | 3.95% |
| Equity Weight | 98.87% |
| Equity Cost | 14.97% |
| WACC | 14.84% |
| Leverage | 1.15% |
InMode Ltd. : Quality Control
InMode Ltd. passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| CHEMM.CO | ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in … |
| EUZ.DE | Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and … |
| GBT.PA | Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and … |
| XVIVO.ST | Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ChemoMetec
A-Score
1-Year Total Return ->
🥈
InMode
A-Score
1-Year Total Return ->
🥉
Guerbet
A-Score
1-Year Total Return ->
4
CellaVision
A-Score
1-Year Total Return ->
5
Eckert & Ziegler
A-Score
1-Year Total Return ->
6
